SCHEMBL16384393

SCHEMBL16384393

CNCCN1CCN(C(=O)C(C)C)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.50
CARM1 Q86X55 7/20 0.48
PRMT6 Q96LA8 7/20 0.48
PRMT8 Q9NR22 2/20 0.48
POLB P06746 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
PRMT1 Q99873 1/20 0.43
TP53 P04637 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HRH2 P25021 1/20 0.40
HRH1 P35367 1/20 0.40
MTNR1B P49286 1/20 0.39
PIK3CD O00329 1/20 0.38
CHRNB2 P17787 1/20 0.38
CHRNA3 P32297 1/20 0.38
CHRNA4 P43681 1/20 0.38
CHRNB3 Q05901 1/20 0.38
CHRNA6 Q15825 1/20 0.38
MEN1 O00255 1/20 0.37
CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL39855 0.79 CARM1 (0.54) CYP2C19CARM1PRMT6PRMT8PRMT1
SCHEMBL3314840 0.79 CARM1 (0.54) CYP2C19CARM1PRMT6PRMT8PRMT1
SCHEMBL1098678 0.79 POLB (0.47) CYP2C19POLBRXFP1TP53SMN1; SMN2
SCHEMBL1098682 0.79 POLB (0.50) CYP2C19POLBRXFP1HRH2HRH1
SCHEMBL13452456 0.79 HRH2 (0.48) CYP2C19POLBRXFP1HRH2HRH1
SCHEMBL24127292 0.79 CARM1 (0.48) CYP2C19CARM1PRMT6PRMT8PRMT1
SCHEMBL13347946 0.79 CARM1 (0.48) CYP2C19CARM1PRMT6PRMT8PRMT1
SCHEMBL18908760 0.78 SMN1; SMN2 (0.47) CYP2C19POLBRXFP1TP53SMN1; SMN2
SCHEMBL11501237 0.78 CARM1 (0.52) CYP2C19CARM1PRMT6PRMT8POLB
SCHEMBL24208750 0.78 POLB (0.46) CYP2C19POLBRXFP1TP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150005319-A1 MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 ENSEMBLE THERAPEUTICS CORPORATION 2015-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150005319-A1 MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 IL17A, IL15, IL2 CYP2C19 95/4885CARM1 2553/4885PRMT6 2369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.